REVIEW ARTICLE

Critical Exploration and Updated Review on COVID-19

Nikhita M. Chambhare[1], Prachi A. Shahu[2], Garima Raj[2], Sukriti Singh[2], Pranita Jirvankar[1]

[1]Department of Pharmaceutical Chemistry, Datta Meghe College of Pharmacy, Datta meghe institute of Higher Education and Research (DU), Wardha, Maharashtra, India, [2]Department of Pharmaceutics, Galgotias College of Pharmacy, Greater Noida, Uttarpradesh, India

Abstract

Coronaviruses (COVID-19) belong to a group of viruses that can harm the respiratory and digestive systems. Everyone is susceptible to respiratory infections, which depend on the illness and can last from a mild cold to more serious illnesses. There are two Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV) cases: Chronic obstructive pulmonary disease and MERS. An updated version of coronavirus, that is, novel coronavirus recently originated in human beings. Coronavirus is the unit thus named as a result of the means that they seem underneath a magnifier. The virus comprises a genetic material core of genetic material encased within a spike-like associate degree envelope. In Latin, the term corona refers to "corona." Coronaviruses can spread from animals to people since they are an ailment that affects animals. MERS-CoV and SARS-CoV can transfer from cats and camels to humans, respectively. On December 31, 2019, a bunch of cases of respiratory illness of unidentified cause, within the town of the city, Hubei region in China, informed by the World Health Organization (WHO). All revealed inherited sequences of SARS-CoV-2 remote from human cases square measure analogous. In 2020, an antecedently unidentified latest virus was known, afterward called the 2019 novel coronavirus, and the section obtained from cases and studies of the virus' biological science direct the reason for happening. The WHO recognized the existence of this novel coronavirus in the year 2020. It was named COVID-19 or Coronavirus Infectious Disease-2019. The illness caused by the virus, SARS-CoV-2, is known as COVID-19.

Key words: Coronaviridae, Coronavirus, Endemic, MERS-CoV, Pandemic

INTRODUCTION

The World Health Organization (WHO) has declared the 2019 Coronavirus unwellness (COVID-19) an endemic to prevent the spread of the virus, world coordinate efforts are needed. It is a disease that spreads across an oversized geographical region and affects an oversized proportion of the population.[1]

A cluster of respiratory disease cases with a degree unknown cause was in keeping with the administrative unit on New Year's Day eve, 2019, in Metropolis, Hubei Province, China. Electron microscopy research discovered that the point may be a clove-shaped polymer along with 3 S1 heads and trimeric S2 stalk.[2] In the Gregorian calendar month of 2020, the administrative unit elects this novel coronavirus as COVID-19. SARS-CoV is the virus's name and COVID-19 is the sickness it causes. As of May 15, 2020, there had been over 4,444,670 cases in 188 countries, with a whole of 302,493 fatalities found.[3,4]

The only human case of COVID-19, an infection produced by the new coronavirus that causes COVID-19 and was later known as SARS-CoV-2, was first reported by officers in Wuhan, China, in December 2019.[5] Exposition research by Chinese establishments has known human cases with the inception of symptoms in early December 2019, whereas a numeral of the earliest best-known cases had a linkage to a wholesale grocery store in Wuhan. Several of the initial patients were either stall homeowners, market staff, or regular guests of the present market.[6]

Address for correspondence:
Prachi A. Shahu, Galgotias College of Pharmacy, Greater Noida, Uttar Pradesh, India. Phone: 09711302273.
E-mail: prachi.shahu10@gmail.com

Received: 10-07-2023
Revised: 11-11-2023
Accepted: 02-12-2023

STRUCTURE

Coronavirus is dangerous and other animals' health. In 2002 and 2003, 8000 persons were infected with the SARS-CoV, which had a 10% death rate. More than 1700 people have died since 2012, with a fatality rate of 36%.[7]

The family of Coronaviridae includes coronaviruses, which is part of the Nidoviralesorder. Alphacoronavirues, Betacoronaviruses, Gammacoronaviruses, Deltacoronaviruses, and Omicron[8] are the five genera. The alpha and beta coronaviruses transmit a disease to mammals, the gammacoronaviruses pass on a disease to birds and the delta coronaviruses communicate a disease to both mammals and birds. Alphacoronaviruses include the Human coronavirus NL63, procline transmissible gastroenteritis coronavirus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus.[9,10] Examples of beta coronaviruses include SARS-CoV, Middle Eastern Respiratory Syndrome Coronavirus (MERS-CoV), bat coronavirus HKU4, mouse infectious disease coronavirus, bovine coronavirus (BCoV), and human coronavirus OC4. The porcine delta coronavirus and the vertebrate infectious respiratory disease coronavirus are examples of delta and gamma coronaviruses, respectively.[7] Coronaviruses are a group of many positive-stranded ribonucleic acid viruses with a large envelope. Among all ribonucleic acid viruses, they placed the largest order, typically ranging from 7 Kb to 32 Kb.[11]

The nucleocapsid supermolecule (N) and Associate in Nursing envelope[12] combine to form a spiral capsid that houses the ordering. Include at least three structural supermolecules or the organism's outermost envelope.[13] The spike supermolecule (S) facilitates the virus's entry into host cells whereas the membrane macromolecule (M) and envelope supermolecule (E) must be essential for virus elaboration. A few coronaviruses can encrypt the hemaglutinin-esterase supermolecule molecule connected to the envelope.[14,15] The spike may play a critical role in determining host variation and response in addition to mediating virus entrance. It may also be a substantial inducer of host immune responses. One of these structural proteins, called the spike, causes coronaviruses to seem to have enormous protrusions from their surface.[16]

S1-CTDs are in charge of identifying the macromolecule receptors ACE2, APN, and DPP4.[17,18] A main component and a receptor-binding motif, both of which are subdomains, are present in the SARS-CoV S1-CTD. The primary structure might consist of five parallel strands. SARS-CoV S1-CTD, which is under pressure to change, closely follows these areas of concern. SLCoVs, coronaviruses that resemble SARS, have been shown to infect human cells.[19] In the contrary side, DPP4 makes a homodimer and all of its compounds have the enzyme structure and a propeller structure.

Camel DPP4's intact VBM residues make it an effective MERS-CoV receptor.[20] It is distinct from the SARS-CoV S1-CTD's single-layer, five-stranded-sheet core structure. A head-to-head chemical compound and a seahorse-shaped structure were both present in the ectodomain of APN.[21]

The S1-CTDs appear to have undergone a significant amount of different development to produce separate core structures.[16] In structural and clinical studies, two large hydrophobic layers have been identified at the S1-NTD/CEACAM1 connection.[22,23] Human galectins overlap with BCoV S1-NTD in this area, although galectins lack a ceiling-like structure and have an open sugar-binding site.[24] First, the related structural topology of the S1 subunits in the two separate genera of coronaviruses (alpha and beta) suggests that the S1 subunits originated from a common organic process.[25]

The coronavirus spike contains three segments: a rapid object tail, a membrane affix with one pass, and an enlarged ectodomain.[28] The receptor-binding unit S1 and the membrane fusion unit S2 make the ectodomain. According to S2 analytical investigations, the spike might be a clove-shaped complex with three S1 heads and a trimeric S2 stalk.[29] The moment the virus penetrates the host cell, S1 binds to a receptor to allow for attaching to organisms, and S2 joins the host and organism membranes to allow for genome entry. The first and most important processes in the coronavirus infection cycle are receptor binding and membrane fusion, which also serve as the main targets for human inventions.[30,31] The various classes of Corona virus has been depicted in Figure 1.

SIGNS AND SYMPTOMS

Most common signs

- Cough
- Fatigue
- Fever
- Loss of taste and smell

Less frequent signs[32]

- Throbbing Head
- Spasm
- Irritated eyes
- Discomfort on swallowing
- Urticaria
- Dysentery
- Yellowing of the nails

Severe symptoms include

- Dyspnea
- Asthma
- Disruption in speaking
- Disorientation
- Chest pain



Figure 1: Spike Proteins and Coronavirus Introduction. (a) Coronavirus classification.[26] (b) A diagram showing the design of perfusion coronavirus case rise. (c)The S1 N-terminal domain (S1-NTD), S1 C-terminal domain (S1-CTD), fusion peptide (FP), and the repeat regions N and C (HR-N and HR-C) are all represented in, along with the domain structure of coronavirus spikes. The scissors represent two coronavirus spikes with chemical action sites. (d) A description of the structure and roles played by coronavirus spikes.[27]

If you are experiencing severe symptoms, get medical help right once. Call your doctor or the treatment facility frequently.[33,34]

Once a person acquires the virus, it typically takes 5–6 days for indications to show up; however, this may require as much as 14 days.[34,35]

CAUSES, RISK FACTORS, AND COMPLICATIONS

The novel coronavirus known as SARS-CoV-2, or severe acute metastasis syndrome coronavirus 2019, is the triggering agent of coronavirus disease 2019 (COVID-19).[36,37]

Many new things are being learned about how the virus spreads over time, although it appears to only affect humans.[38] According to studies, it can transmit from person to person when they are close (within about two meters or six feet).

When a person with this virus coughs, sneezes, or talks, tiny droplets are released that transmit the infection.[39] These droplets will be sucked in or come into someone's mouth or nose who is standing close by. It could spread even if someone touches their lips, nose, or eyes after coming into contact with an object which has the infectious agent on it.

Complications can include

Viral infections; blood clots; heart problems; pneumonia and breathing difficulties; organ failure in multiple organs; acute respiratory distress syndrome, a severe lung condition that reduces the amount of oxygen that reaches the organs through the bloodstream; acute kidney injury; and additional bacterial.[40,41]

DIAGNOSIS

Sample assortment

Most well-liked samples-Nasal and throat samples are transferred in a vital transport medium under refrigeration

Alternate methods include endotracheal aspiration and body cavity swabs that must be carried inside the cold chain after being combined with an infectious agent transport medium.[42]

General tips

- When collecting specimens, wear appropriate personal protective equipment (droplet and call protection for URT specimens; mobile protection for LRT specimens).
- After the specimen has been collected, maintain proper infection management.
- Entry to guests or assistants is restricted during the sample collection.

- Each specimen requirement must be completed, and all waste must be disposed of properly.[43]

Gasping specimen assortment method

- Lower tract – Bronchoalveolar irrigation, cartilaginous tube aspirate, sputum.
- Upper tract – Bodily cavity swab and cavum swab.[44]

Using a throat swab, for example, a cavum swab

Turn the patient's head backward by 70 degrees. While wiping the swab over each tonsillar pillar and the posterior cavity, avoid making contact with the tongue, teeth, or gums. Use only swabs that have plastic shafts made of synthetic fibers. Do not use metal or picket-shafted alginate swabs. Swabs should be put in sterile tubes with 2–3 mL of microbe transport media as soon as possible.[45,46]

Combination nasal-throat swab

Turn the patient's head back to a position of 70 degrees. Gently spin the swab and insert all but one of the tips into the naris (until resistance is felt at the turbinates). Rotate the swab repeatedly against the nasal wall in other nostrils while inserting a constant swab into a constant tube, interrupting the applier tip.

Cavity swab

Lift the patient's head back seventy degrees. Continue until resistance is felt or there is a space from the patient's ear to the naris by inserting a flexible swab into the patient's naris parallel to the surface (not upwards). Swab is rolled and softly rubbed. Allow the swab to absorb secretions for a short period before removing it.[47]

Clinicians may obtain lower tract samples when they are promptly available (such as in patients who are automatically aerated). Hospitalized COVID patients (severe cases with confirmed COVID-19 infections) should have further upper tract samples taken to demonstrate the removal of the bacteria.[48,49]

Counseled check

For diagnosis, a period or standard reverse transcription–polymerase chain reaction, fast antigen check was advised. At present, it does not appear that SARS-CoV-2 protein testing was advised to detect COVID-19 infection.[50]

Patients with COVID-19 have many infections, including viral, bacterial, and fungal metastatic infections. Based on local medical specialization and clinical symptoms, consider additional likely aetiologies, as needed (e.g., influenza, different metastatic viruses, malaria, broken bone fever, and typhoid fever).[51,52]

Preferably before starting antibiotic therapy for COVID-19 patients who are critically ill, examine blood cultures.[53]

PREVENTION

Interference within the social unit

The following steps will be followed to stop the virus from spreading, if someone within the social group contracts it develops COVID-19:[54,55]

- Remaining in a place that is far away.
- Give your hands a 20-s soap-and-water wash. Use a disinfectant containing hr alcohol instead.

If possible, use a private bathroom.[56]

- After being harmed, cleanse and clean the restroom surface.
- Donning a mask to target public spaces in the past.
- Avoid sharing food and beverages with those who are healthy.
- Putting on gloves when cleaning and sanitizing any common surfaces.[57]

Workplace interference

Staff and employees will reduce the possibility of coronavirus transmission at the workplace by: [58]

- Regularly sanitizing and cleaning all surfaces.
- Posters that encourage frequent hand washing, the provision of hand sanitizer, and easy access to soap and water.
- Making it crystal obvious to employees that, despite their fragility, people may have to be forced to remain in their residence, those having any COVID-19 symptoms.[59]
- Try to conduct conferences through conference calls rather than in-person meetings.
- Requesting whenever possible that employees work from home.
- Providing people with the best possible social, financial, and psychological support to help them limit physical contact.[60]

How and when to use face masks

- The WHO states that individuals should only be required to wear a mask while coughing, sneezing, or caring for someone who has COVID-19.
- Face masks are only useful when they are applied correctly. Use and remove a mask correctly by following these steps.[61,62]
  a. Without contacting your face or the mask, firstly clean your palm with disinfectant in a duration of 10 s.

b. Make sure the mask covers the mouth and nose entirely, with no gaps between the face and the mask.[63]
c. Do not touch the mask when carrying it.
d. One must wash their hands one more if they contact with the mask while wearing it.
e. Steer clear of reused single-use masks.
f. Avoid writing anything on the mask, such as a name. This damage conceals integrity and lets pollutants in.[64]
g. If a mask gets wet, replace it.
h. Instead of touching the front of the mask to take it off, lift the string at the back.
i. Immediately throw away used masks in a closed trash can, then rewash your hands.

VACCINATION IN INDIA

Covaxin

Bharat Biotech and the National Institute of Virology of the Indian Council of Medical Research (ICMR) have worked together to produce COVAXINTM, India's indigenous COVID-19 vaccine. The Bio-Safety Level-3 high contaminant facility at Bharat Biotech is where this indigenous, inactivated vaccine is designed and manufactured.

The Whole-Virion inactivated SARS-CoV-2 vaccine (BBV152) was accepted by the Drug Controller General of India for Phase 1 clinical trials and Phase 2 human clinical trials with an accommodating, seamless part,[65] followed by a randomized, run, a multicenter research to evaluate the vaccine's antigenicity, reactogenicity, safety, and tolerance.

CoviShield

To determine the safety and immunogenicity of CoviShield (COVID-19 Vaccine), the Serum Institute of India (SII) and the ICMR are jointly conducting a phase ii/iii, Observer-Blind, Randomized, Controlled study.[66,67]

The COVID-19 vaccinations produce immunity to the disease as a result of producing an immune response to the SARS-CoV-2 virus. Through vaccination, one can increase their immunity, which lowers their likelihood of contracting the illness and its effects. If you are exposed to the infection, this immunity aids your defense.[68,69]

Sputnik V

The vaccine agent COVID-19 from Russia which is an adenoviral-based, two-part vaccine against the SARS-CoV-2 coronavirus and Sputnik V (Gam-Covid-Vac). Sputnik V, which was first developed in Russia, employs a weakened virus to deliver minute quantities of an infectious agent and trigger an effect.[70,71]

The beta coronavirus referred to as SARS-CoV-2 was the source of the COVID-19 epidemic, which was slowed down by Sputnik V.[72]

The SARS-CoV-2 coronavirus cistron is integrated during a period when an animal virus-supported vector is used as an immunizing agent. The coronavirus cistron is a "container"-delivered to cells by an animal virus, which also starts building the new coronavirus' envelope proteins, exposing the system to a potential foe. The cistron can be utilized by the cells to deliver the spike macromolecule. The individual's system can handle this.[73,74]

Vaccines for COVID-19 that pass the Phase I and Phase II clinical trials[75]

S. No.	Vaccine's name	Production head
1.	Covaxin	Bharat Biotech.
2.	AstraZeneca	The University of Oxford and British- Swedish company AstraZeneca
3.	Moderna vaccine	Moderna Inc.
4.	BNT162	BioNTech and Pfizer
5.	Sinovac biotech vaccine	Sinovac's Research and Development.
6.	Cansino biologics	Casino Biologics Inc.
7.	Novavax vaccine	Novavax[76]
8.	Sinopharm vaccine	Sinopharm
9.	CureVac vaccine	German Biotech Firm.
10.	Johnson and Johnson vaccine	Johnson and Johnson

MANAGEMENT

Screening, containment, and mitigation

Strategies for screening, containment (or suppression), and mitigation of a plague reduces the peak in health care demand. The goal of screening is to identify increased vital signs associated with the incidence, identify and isolate those who are affected, and adopt additional steps from preventing the virus from circulating. Once the disease has stopped controlling, efforts shift to the mitigation stage.[77-79]

There are steps for reducing the unfolding also lessening its consequences on society and the ecological system. It is also possible to implement a combination of containment and mitigation strategies over time.[80]

Reducing the necessary replica range to one will stop the pandemic, which requires extra harsh measures for suppression.[81]

Contact tracing

Health authorities must utilize contact tracing to locate the source of the virus and stop its spread. Amnesty International and almost 100 other groups have issued a press release called for minimizing barrier on such type of police inquiry due to privacy concerns raised by governments' using GPS coordinates from cellular devices are used for this.[82]

Health care

The UN agency defines Boosting the ability and refocusing efforts for COVID-19 patients' needs as a fundamental natural event reaction live.[83] In addition to concentrating lab facilities on COVID-19 testing, removing optional treatments if feasible, eliminating and uninfected COVID-19-confirmed individuals, also enhancing the number of medical wellness capacities through staff trainers and expanding the amount of supplied vents and other equipment, the ECDC and the European Regional Office of the UN agency has released recommendations for clinics and first aid facilities. Non-emergency attention services are offered in several places.[84,85] Some firms are employing 3D printing to produce things like nasal swabs and ventilator parts due to shortages of volume in the conventional distribution networks.

Management of COVID-19: Symptomatic treatment

Management of delicate cases

Patients with verified or identified delicate COVID-19 are confined within a containment area to break the chain of transmission.[86] Patients with sensitive illnesses may present to the outpatient or first-case department or may be identified through community outreach initiatives like home visits or telemedicine.

Under the conditions stated in the online home isolation recommendations, mild cases can be treated at COVID Care Centers, First Referral Units, Community Health Centers, sub-district and district hospitals, or reception.[87,88]

The patient has monitored their daily temperature, vitals, and SpO_2 levels (atomic oxygen saturation).

Management of moderate cases

To prevent the transmission of the infection, people suffering from mild corona disease (pneumonia) that have been diagnosed or detected should be quarantined.[89] Individuals having mild illness might visit an emergency facility or a primary care office, or they might be identified by community police investigation techniques like active house-to-house searches or telemedicine.[90]

The process clinical assessment parameters are atomic number 8 saturation (SpO_2) of but 94 on ambient air (range 90–94%)[91] and rate of respiration of quite or adequate to 24.

Such patients will be segregated in a special COVID Health Center (DHDC).[92,93]

Management of severe cases

Early confirming medical aid and observance.

Provide individuals the supplement gas medical aid suffering from Severe COVID along with metabolic anxiety, oxygen deprivation, or trauma.[94,95] Start providing gastric assistance at a rate of 5 L/min, monitoring flow rates to ensure effectiveness for non-pregnant people and SpO_2 of 92–96% in patients becoming a mother. Youngsters with urgent signals ought to obtain gas medical aid throughout resurgence to target SpO_2 ≥94%.[96] Pulse oximeters, functional gas devices, and single-use, throw-away oxygen-delivery systems need to be available in all protective facilities for individuals with severe COVID. If a patient has severe COVID then manage their fluid intake cautiously, when once there is a lack of data to support shock.[97]

Management of hypoxemic metabolism failure and respiratory disease

Once an individual with metabolism disturbance has given up with customary gas medical aid, you should be able to identify extremely low oxygen levels of metabolism insufficiency. Even after receiving gas through a mask with a bag (which typically requires stream speed of 9–14 L/min to keep all bags expanded, use FiO_2 0.60–0.95), patients may still have elevated work of breathing or hypoxemia. Usually, respiratory organ ventilation-perfusion mate or shunt cause hypoxemic metabolism failure in respiratory disease, and mechanical ventilation is frequently required.[98-100]

CONCLUSION

This review describes the diverse overview for the COVID-19. The COVID-19 pandemic has been a defining global crisis that has fundamentally reshaped the way we live, work, and interact with the world. This review paper has examined various aspects of the COVID-19 virus, from its origins and transmission dynamics to the development of vaccines and the impact on health-care systems and society as a whole.

CONFLICTS OF INTEREST

The authors have no conflicts of interest to declare. All coauthors have seen and agree with the contents of the manuscript.

REFERENCES

1. Amodio E, Vitale F, Cimino L, Casuccio A, Tramuto F. Outbreak of novel coronavirus (SARS-Cov-2): First evidences from international scientific literature and pending questions. Healthcare (Basel) 2020;8:51.
2. Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q, Meredith HR, *et al.* The incubation period of coronavirus disease 2019 (COVID-19) from publicly reported confirmed cases: Estimation and application. Ann Intern Med 2020;172:577-82.
3. Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF. The proximal origin of SARS-CoV-2. Nat Med 2020;26:450-2.
4. Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: Emergence, transmission, and characteristics of human coronaviruses. J Adv Res 2020;24:91-8.
5. Pinto D, Park YJ, Beltramello M, Walls AC, Tortorici MA, Bianchi S, *et al*. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Nature 2020;583:290-5.
6. Yan Y, Shin WI, Pang YX, Meng Y, Lai J, You C, *et al.* The first 75 days of novel coronavirus (SARS-CoV-2) outbreak: Recent advances, prevention, and treatment. Int J Environ Res Public Health 2020;17:2323.
7. Li F. Structure, function, and evolution of coronavirus spike proteins. Annu Rev Virol 2016;3:237-61.
8. Chen Y, Liu Q, Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol 2020;92:418-23.
9. Lauber C, Goeman JJ, Parquet MC, Nga PT, Snijder EJ, Morita K, *et al.* The footprint of genome architecture in the largest genome expansion in RNA viruses. PLoS Pathog 2013;9:e1003500.
10. Gélinas AM, Boutin M, Sasseville AM, Dea S. Bovine coronaviruses associated with enteric and respiratory diseases in Canadian dairy cattle display different reactivities to anti-HE monoclonal antibodies and distinct amino acid changes in their HE, S and ns4.9 protein. Virus Res 2001;76:43-57.
11. Li F. Receptor recognition mechanisms of coronaviruses: A decade of structural studies. J Virol 2015;89:1954-64.
12. Kammerer R, Stober D, Singer BB, Obrink B, Reimann J. Carcinoembryonic antigen-related cell adhesion molecule 1 on murine dendritic cells is a potent regulator of T cell stimulation. J Immunol 2001;166:6537-44.
13. Pourrajab F, Zare-Khormizi MR, Sheikhha MH. Molecular basis for pathogenicity of human coronaviruses. Infect Drug Resist 2020;13:2385-405.
14. Ghosh S. Virion structure and mechanism of propagation of coronaviruses including SARS-CoV 2 (COVID-19) and some meaningful points for drug or vaccine development. Preprints 2020;2020080312.
15. Guo H, Hu BJ, Yang XL, Zeng LP, Li B, Ouyang S, *et al.* Evolutionary arms race between virus and host drives genetic diversity in bat severe acute respiratory syndrome-related coronavirus spike genes. J Virol 2020;94:e00902-20.
16. Hon CC, Lam TY, Shi ZL, Drummond AJ, Yip CW, Zeng F, *et al.* Evidence of the recombinant origin of a bat severe acute respiratory syndrome (SARS)-like coronavirus and its implications on the direct ancestor of SARS coronavirus. J Virol 2008;82:1819-26.
17. Rasmussen HB, Branner S, Wiberg FC, Wagtmann N. Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog. Nat Struct Biol 2003;10:19-25.
18. Hulswit RJ, de Haan CA, Bosch BJ. Coronavirus spike protein and tropism changes. Adv Virus Res 2016;96:29-57.
19. Walls AC, Tortorici MA, Snijder J, Xiong X, Bosch BJ, Rey FA, *et al.* Tectonic conformational changes of a coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A 2017;114:11157-62.
20. Chen L, Lin YL, Peng G, Li F. Structural basis for multifunctional roles of mammalian aminopeptidase N. Proc Natl Acad Sci U S A 2012;109:17966-71.
21. Artika IM, Dewantari AK, Wiyatno A. Molecular biology of coronaviruses: Current knowledge. Heliyon 2020;6:e04743.
22. Ströh LJ, Stehle T. Glycan engagement by viruses: Receptor switches and specificity. Annu Rev Virol 2014;1:285-306.
23. Bickerton E, Maier HJ, Stevenson-Leggett P, Armesto M, Britton P. The S2 subunit of infectious bronchitis virus beaudette is a determinant of cellular tropism. J Virol 2018;92:e01044-18.
24. Ou X, Guan H, Qin B, Mu Z, Wojdyla JA, Wang M, *et al.* Crystal structure of the receptor binding domain of the spike glycoprotein of human betacoronavirus HKU1. Nat Commun 2017;8:15216.
25. Baker M, Prasad BV. Rotavirus cell entry. Curr Top Microbiol Immunol 2010;343:121-48.
26. Krueger RL. *In vitro* and *in vivo* Characterization of the Infection Efficiency of a Modified Retrovirus Envelope Glycoprotein for Targeting Gene Transduction. USA: The University of Tennessee Health Science Center; 2013.
27. Xu Y, Liu Y, Lou Z, Qin L, Li X, Bai Z, *et al.* Structural basis for coronavirus-mediated membrane fusion. Crystal structure of mouse hepatitis virus spike protein fusion core. J Biol Chem 2004;279:30514-22.
28. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, *et al.* Immunogenicity and structures of a rationally designed prefusion MERS-CoV spike antigen. Proc Natl Acad Sci U S A 2017;114:E7348-57.
29. Maurer UE, Sodeik B, Grünewald K. Native 3D intermediates of membrane fusion in herpes simplex virus 1 entry. Proc Natl Acad Sci U S A 2008;105:10559-64.
30. Krueger DK, Kelly SM, Lewicki DN, Ruffolo R, Gallagher TM. Variations in disparate regions of the murine coronavirus spike protein impact the initiation of membrane fusion. J Virol 2001;75:2792-802.

31. Belouzard S, Millet JK, Licitra BN, Whittaker GR. Mechanisms of coronavirus cell entry mediated by the viral spike protein. Viruses 2012;4:1011-33.
32. Bosch BJ, Bartelink W, Rottier PJ. Cathepsin L functionally cleaves the severe acute respiratory syndrome coronavirus class I fusion protein upstream of rather than adjacent to the fusion peptide. J Virol 2008;82:8887-90.
33. Meng T, Cao H, Zhang H, Kang Z, Xu D, Gong H, *et al*. The insert sequence in SARS-CoV-2 enhances spike protein cleavage by TMPRSS. Biorxiv 2020;2020-2.
34. van Doremalen N, Miazgowicz KL, Milne-Price S, Bushmaker T, Robertson S, Scott D, *et al.* Host species restriction of Middle East respiratory syndrome coronavirus through its receptor, dipeptidyl peptidase 4. J Virol 2014;88:9220-32.
35. McLellan JS, Yang Y, Graham BS, Kwong PD. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 2011;85:7788-96.
36. Swanson K, Wen X, Leser GP, Paterson RG, Lamb RA, Jardetzky TS. Structure of the Newcastle disease virus F protein in the post-fusion conformation. Virology 2010;402:372-9.
37. Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Brüggen MC, *et al.* Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020;75:1564-81.
38. Forterre P. The origin of viruses and their possible roles in major evolutionary transitions. Virus Res 2006;117:5-16.
39. Cao Y, Liu X, Xiong L, Cai K. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2: A systematic review and meta-analysis. J Med Virol 2020;92:1449-59.
40. Hall CB, Douglas RG Jr., Geiman JM. Possible transmission by fomites of respiratory syncytial virus. J Infect Dis 1980;141:98-102.
41. McFee DR. COVID-19 medical management including World Health Organization (WHO) suggested management strategies. Dis Mon 2020;66:101068.
42. Swierkosz EM, Flanders R, Melvin L, Miller JD, Kline MW. Evaluation of the Abbott TESTPACK RSV enzyme immunoassay for detection of respiratory syncytial virus in nasopharyngeal swab specimens. J Clin Microbiol 1989;27:1151-4.
43. Li Z, Yi Y, Luo X, Xiong N, Liu Y, Li S, *et al.* Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020;92:1518-24.
44. Austrian K, Pinchoff J, Tidwell JB, White C, Abuya T, Kangwana B, *et al*. Preprint-COVID-19 related knowledge, attitudes, practices and needs of households in informal settlements in Nairobi, Kenya. 2020.
45. Wang J, Yang W, Pan L, Ji JS, Shen J, Zhao K, *et al.* Prevention and control of COVID-19 in nursing homes, orphanages, and prisons. Environ Pollut 2020;266:115161.
46. Battista RA, Ferraro M, Piccioni LO, Malzanni GE, Bussi M. Personal protective equipment (PPE) in COVID 19 pandemic: Related symptoms and adverse reactions in healthcare workers and general population. J Occup Environ Med 2021;63:e80-5.
47. Fang B, Meng QH. The laboratory's role in combating COVID-19. Crit Rev Clin Lab Sci 2020;57:400-14.
48. Tiep BL. Disease management of COPD with pulmonary rehabilitation. Chest 1997;112:1630-56.
49. Polycarpou A, Howard M, Farrar CA, Greenlaw R, Fanelli G, Wallis R, *et al.* Rationale for targeting complement in COVID-19. EMBO Mol Med 2020;12:e12642.
50. Yi Y, Lagniton PN, Ye S, Li E, Xu RH. COVID-19: What has been learned and to be learned about the novel coronavirus disease. Int J Biol Sci 2020;16:1753-66.
51. Khuroo MS. Chloroquine and hydroxychloroquine in coronavirus disease 2019 (COVID-19). Facts, fiction and the hype: A critical appraisal. Int J Antimicrob Agents 2020;56:106101.
52. Shastri S, Singh K, Kumar S, Kour P, Mansotra V. Time series forecasting of Covid-19 using deep learning models: India-USA comparative case study. Chaos Solitons Fractals 2020;140:110227.
53. Funk CD, Laferrière C, Ardakani A. A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Front Pharmacol 2020;11:937.
54. Bilotta C, Perrone G, Adelfio V, Spatola GF, Uzzo ML, Argo A, *et al.* COVID-19 Vaccine-related thrombosis: A systematic review and exploratory analysis. Front Immunol 2021;12:729251.
55. Aggarwal KK, Ganguly NK. In quest of a COVID-19 vaccine: A race against time. Physician 2020;6:2.
56. Sengupta S, Jha MK. Social policy, COVID-19 and impoverished migrants: Challenges and prospects in locked down India. Int J Community Soc Dev 2020;2:152-72.
57. Massand A, Lodi MK, Ambreen L. Atmanirbhar Bharat: Economic, legal, and social aspects. Int J Manage 2020;11:1038-46.
58. Paul A, Chatterjee S, Bairagi N. Covid-19 transmission dynamics during the unlock phase and significance of testing. medRxiv 2020;2020-08.
59. Garrett RM, Hinchliffe K, Montgomery R. The Government of India Ministry of Human Resource Development. Department of Education: Report on Andhra Pradesh Primary Education Project.
60. Huang Y, Khanna T. Can India overtake china? Foreign Policy 2003;137:74-81.
61. Sharma R, Gupta S. Bharat towards Atmanirbharta: A Twitter based analysis using NVIVO. J Content Community Commun 2021;13:58-65.
62. Jha R, Sharma A. India's Pharmaceutical Industry: Global Supply Chain and Governance in the Post-COVID-19 World; 2020. Available from: https://ssrn3622794 [Last accessed on 2023 Mar 12].
63. Ayati N, Saiyarsarai P, Nikfar S. Short and long term impacts of COVID-19 on the pharmaceutical sector. Daru 2020;28:799-805.

64. Phua J, Weng L, Ling L, Egi M, Lim CM, Divatia JV, *et al.* Intensive care management of coronavirus disease 2019 (COVID-19): Challenges and recommendations. Lancet Respir Med 2020;8:506-17.
65. Lucivero F, Hallowell N, Johnson S, Prainsack B, Samuel G, Sharon T. COVID-19 and contact tracing apps: Ethical challenges for a social experiment on a global scale. J Bioeth Inq 2020;17:835-9.
66. Grasselli G, Pesenti A, Cecconi M. Critical care utilization for the COVID-19 outbreak in Lombardy, Italy: Early experience and forecast during an emergency response. JAMA 2020;323:1545-6.
67. Thevarajan I, Buising KL, Cowie BC. Clinical presentation and management of COVID-19. Med J Aust 2020;213:134-9.
68. Afolabi OA, Abboah-Offei M, Namisango E, Chukwusa E, Oluyase AO, Luyirika EB, *et al.* Do the clinical management guidelines for Covid-19 in African countries reflect the African quality palliative care standards? A review of current guidelines. J Pain Symptom Manage 2021;61:e17-23.
69. Lentz S, Roginski MA, Montrief T, Ramzy M, Gottlieb M, Long B. Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS. Am J Emerg Med 2020;38:2194-202.
70. The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) - China, 2020. China CDC Wkly 2020;2:113-22.
71. Pujari BS, Shekatkar S. Multi-city modeling of epidemics using spatial networks: Application to 2019-nCov (COVID-19) coronavirus in India. Medrxiv 2020;3: 2020-03.
72. Sultana S, Shafique I, Majeed N, Jamshed S, Shahani AK, Qureshi F. Impact of Covid-19 outbreak on psychological health-The case of Bangladesh. Heliyon 2021;7:e06772.
73. Bastos RS, de Lima LR, Neto MF, Maryam, Yousaf N, Cruz JN, *et al*. Design and identification of inhibitors for the spike-ACE2 target of SARS-CoV-2. Int J Mol Sci 2023;24:8814.
74. Guan WJ, Chen RC, Zhong NS. Strategies for the prevention and management of coronavirus disease 2019. Eur Respir J 2020;55:200597.
75. Lu S, Lin J, Zhang Z, Xiao L, Jiang Z, Chen J, *et al.* Alert for non-respiratory symptoms of coronavirus disease 2019 patients in epidemic period: A case report of familial cluster with three asymptomatic COVID-19 patients. J Med Virol 2021;93:518-21.
76. Vaira LA, Salzano G, De Riu G. The importance of olfactory and gustatory disorders as early symptoms of coronavirus disease (COVID-19). Br J Oral Maxillofac Surg 2020;58:615-6.
77. AlBahrani S, AlAhmadi N, Hamdan S, Elsheikh N, Osman A, Almuthen S, *et al.* Clinical presentation and outcome of hospitalized patients with COVID-19 in the first and second waves in Saudi Arabia. Int J Infect Dis 2022;118:104-8.
78. Ilie PC, Stefanescu S, Smith L. The role of vitamin D in the prevention of coronavirus disease 2019 infection and mortality. Aging Clin Exp Res 2020;32:1195-8.
79. Sargiacomo C, Sotgia F, Lisanti MP. COVID-19 and chronological aging: Senolytics and other anti-aging drugs for the treatment or prevention of corona virus infection? Aging (Albany NY) 2020;12:6511-7.
80. Tuite AR, Bogoch II, Sherbo R, Watts A, Fisman D, Khan K. Estimation of coronavirus disease 2019 (COVID-19) burden and potential for international dissemination of infection from Iran. Ann Intern Med 2020;172:699-701.
81. Han TH, Chung JY, Kim SW, Hwang ES. Human Coronavirus-NL63 infections in Korean children, 2004-2006. J Clin Virol 2007;38:27-31.
82. Pang J, Wang MX, Ang IY, Tan SH, Lewis RF, Chen JI, *et al.* Potential rapid diagnostics, vaccine and therapeutics for 2019 novel coronavirus (2019-nCoV): A systematic review. J Clin Med 2020;9:623.
83. Cavanagh D. Coronavirus avian infectious bronchitis virus. Vet Res 2007;38:281-97.
84. Barro RJ, Ursúa JF, Weng J. The Coronavirus and the Great Influenza Pandemic: Lessons from the "Spanish flu" for the Coronavirus's Potential Effects on Mortality and Economic Activity. Cambridge: National Bureau of Economic Research; 2020.
85. Koshle H, Kaur R, Basista R. Breakdown of Business and Workers in India: Impact of Corona Virus; 2020. Available from: https://dx.doi.org/10.2139/ssrn.3557544 [Last accessed on 2023 Apr 22].
86. Kundu B, Bhowmik D. Societal impact of novel corona virus (COVID-19 pandemic) in India. Indian J Soc Res 2020;61:105-15.
87. Murray RS, Cai GY, Hoel K, Zhang JY, Soike KF, Cabirac GF. Coronavirus infects and causes demyelination in primate central nervous system. Virology 1992;188:274-84.
88. de Wit E, Rasmussen AL, Falzarano D, Bushmaker T, Feldmann F, Brining DL, *et al.* Middle East respiratory syndrome coronavirus (MERS-CoV) causes transient lower respiratory tract infection in rhesus macaques. Proc Natl Acad Sci U S A 2013;110:16598-603.
89. Filatov A, Sharma P, Hindi F, Espinosa PS. Neurological complications of coronavirus disease (COVID-19): Encephalopathy. Cureus 2020;12:e7352.
90. Adams ML, Katz DL, Grandpre J. Population-based estimates of chronic conditions affecting risk for complications from coronavirus disease, United States. Emerg Infect Dis 2020;26:1831-3.
91. Carod-Artal FJ. Neurological complications of coronavirus and COVID-19. Rev Neurol 2020;70:311-22.
92. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, *et al.* Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med 2020;40:351-60.
93. Li C, Zhao C, Bao J, Tang B, Wang Y, Gu B. Laboratory diagnosis of coronavirus disease-2019 (COVID-19).

Clin Chim Acta 2020;510:35-46.
94. Zhuang Z, Zhao S, Lin Q, Cao P, Lou Y, Yang L, *et al.* Preliminary estimation of the novel coronavirus disease (COVID-19) cases in Iran: A modelling analysis based on overseas cases and air travel data. Int J Infect Dis 2020;94:29-31.
95. Mandal S, Bhatnagar T, Arinaminpathy N, Agarwal A, Chowdhury A, Murhekar M, *et al.* Prudent public health intervention strategies to control the coronavirus disease 2019 transmission in India: A mathematical model-based approach. Indian J Med Res 2020;151:190-9.
96. Goyal K, Chauhan P, Chhikara K, Gupta P, Singh MP. Fear of COVID 2019: First suicidal case in India! Asian J Psychiatr 2020;49:101989.
97. Gupta N, Praharaj I, Bhatnagar T, Vivian Thangaraj JW, Giri S, Chauhan H, *et al.* Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020. Indian J Med Res 2020;151:236-40.
98. Tiwari S, Kumar S, Guleria K. Outbreak trends of coronavirus disease-2019 in India: A prediction. Disaster Med Public Health Prep 2020;14:e33-8.
99. Patrikar S, Poojary D, Basannar DR, Faujdar DS, Kunte R. Projections for novel coronavirus (COVID-19) and evaluation of epidemic response strategies for India. Med J Armed Forces India 2020;76:268-75.
100. Pfaar O, Klimek L, Jutel M, Akdis CA, Bousquet J, Breiteneder H, *et al.* COVID-19 pandemic: Practical considerations on the organization of an allergy clinic-An EAACI/ARIA Position Paper. Allergy 2021;76:648-76.

Source of Support: Nil. **Conflicts of Interest:** None declared.